Daily Stock List
Naked Brand Group, Inc. (NAKD)
RedChip and Vantage Wire reported recently on Naked Brand Group, Inc. (NAKD), and today we are highlighting the Company as “One to Watch” this week here at the QualityStocks Daily Newsletter.
Incorporated in 2009, Naked Brand Group, Inc. manufactures and sells undergarments for men and has a line of products (36 new styles) coming for women in Spring 2014. The Company sells their products through retail stores; as well as online. Naked® has reaped major media exposure having been featured on The View, ABC, FOX LA, and (ET) Canada and on The Dragons' Den.
The Company previously went by the name Naked Boxer Brief Clothing, Inc. They changed their corporate name to Naked Brand Group, Inc. in July of 2012. The Company has their headquarters in British Columbia, Canada. Naked Brand Group’s shares trade on the OTC Markets’ OTCQB.
As a global lifestyle brand, the Company’s focus is on enhancing the architecture of the body. Naked Brand Group currently offers crew neck undershirts, V-neck undershirts, and boxer briefs for men. Every Naked piece is constructed with soft-to-the-touch Italian fabric. This fabric seamlessly forms to one’s body. The sole dedication of the Naked Boxer Brief, designed by Joel Primus, is to faultless design and distinctive comfort.
Naked sells in high-end boutiques and department stores throughout North America. These retail outlets include Nordstrom, Holt Renfrew, Boys'co, Kitson, Akira and Freshpair.com. In addition, a donation from every purchase helps to support Project World Citizen. This is a charity driven to empower and educate the children of Ghana.
Last week, Naked Brand Group announced the launch of NKDunderwear.com. This is an e-commerce store shipping to the United States, Canada and select countries around the world. The design of the Company’s NKD line is for the 18-25 year old male who is brand savvy and appreciates quality underwear and undershirts. NKD's spring and summer 2013 collection includes a Cotton Modal blend assortment, and a Microfiber line in an array of masculine colors.
The NKD line offers distinctive styling, quality construction and rich fabrics. They’re offered at prices that accommodate the buying habits of the younger demographic. NKD was launched at Holt Renfrew's discount chain, HR2, this spring. The NKD line has achieved significant results in terms of sales and brand recognition.
We have Naked Brand Group, Inc. (NAKD) locked on our radar screens as “One to Watch” this week here at the QualityStocks Daily Newsletter.
Naked Brand Group, Inc. (NAKD), closed Monday's trading session at $1.16, up 3.57%, on 38,850 volume with 33 trades. The average volume for the last 60 days is 16,657 and the stock's 52-week low/high is $0.70/$1.35.
Porto Energy Corp. (PEC.V)
Today we are reporting on Porto Energy Corp. (PEC.V), here at the QualityStocks Daily Newsletter.
Porto Energy Corp. is a global oil and gas company that engages in the exploration of crude oil and natural gas in Portugal; this includes the appraisal of a gas discovery. Headquartered in The Woodlands, Texas, the Company, by way of their wholly owned subsidiary, Mohave Oil and Gas Corp. holds working interests in seven concessions in Portugal’s Lusitanian Basin totaling 1.6 million net acres. Porto Energy lists on the TSX Venture Exchange, and on the OTC Pink Current Information under the ticker symbol “PNRFX”.
Through their exploration efforts so far, the Company has identified the aforementioned seven major exploration trends over their concessions and generated more than 45 prospects and leads. These include conventional and unconventional oil and gas resource targets. Porto Energy’s strategy is a balanced appraisal and exploration drilling approach that targets oil and gas prospects. Their focus is on drilling in the Pre-salt and evaluating the Lias tight oil play onshore Portugal. The Company will continue to seek partnerships to go after higher risk and higher cost assets.
In June, Porto Energy announced that their joint venture partner in the Aljubarrota-3 concession, Petróleos de Portugal–Petrogal, S.A. (Galp), exercised their option to become the operator of the concession, pursuant to the terms of the definitive farmout agreement signed by the two companies in June of 2012. Assignment of operatorship is subject to approval by the Portugese government department, Direcção Geral de Energia e Geologia (DGEG).
Mr. Joseph P. Ash, President and Chief Executive Officer of Porto Energy, said, “Galp’s exercise of their option to operate the Aljubarrota-3 concession clearly demonstrates their interest and belief in the potential of this asset. While we retain an equal working interest in the concession and expect to participate fully in determining the strategic direction of future exploration activities; transitioning to a non-operated role will provide us with improved financial and operational flexibility going forward.”
Porto Energy Corp. (PEC.V), closed Monday's trading session at $0.035, even for the day, on 59,100 volume. The stock's 52-week low/high is $0.02/$0.26.
Colossus Minerals, Inc. (CSI.TO)
Streetwise Reports reported previously on Colossus Minerals, Inc. (CSI.TO), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Colossus Minerals, Inc. is an exploration and development company with corporate headquarters in Toronto, Ontario. The Company’s principal focus is to advance the Serra Pelada project (75 percent owned), located in Brazil, into production. Serra Pelada is in the mineral prolific Carajas region near the towns of Curionopolis and Parauapebas, Pará State, northern Brazil, where there is premier access and infrastructure. Colossus Minerals lists on the Toronto Stock Exchange and on the OTCQX International under the trading symbol “COLUF”.
The Serra Pelada Mine is a joint venture between Colossus and Cooperativa de Mineração dos Garimpeiros de Serra Pelada (COOMIGASP) located in the State of Pará, Brazil. Discovered in 1979, the Serra Pelada project is host to one of the highest grade gold and platinum group metal (PGM) deposits in the world. Between 1980 and 1986 Serra Pelada was host to the largest precious metals rush in Latin American history. In March 2010, the Company successfully acquired 774 Hectares of additional ground adjoining Serra Pelada. The ownership structure of the total land package remains 75 percent to Colossus and 25 percent to COOMIGASP.
Recently, Colossus Minerals provided a development update for their Serra Pelada gold-platinum-palladium Mine. They remain on schedule for initial production in the third quarter of 2013 at a rate of 250 tonnes per day (tpd). Current planning indicates a ramp-up to 1,000 tpd is achievable by the end of the first quarter of 2014.
Colossus Minerals has substantially completed their bulk sample program. Additional development is ongoing in the Central Mineralized Zone (CMZ) for grade control purposes and to continue building a stockpile ahead of process plant commissioning. The Company now has approximately 2,500 tonnes of material on the run of mine (ROM) pad. This includes lower grade halo mineralization and CMZ material. Assays are pending and initial grade reconciliation ongoing. Project construction is currently 85 percent complete.
Colossus Minerals, Inc. (CSI.TO), closed Monday's trading session at $1.22, up 20.79%, on 1,189,318 volume. The stock's 52-week low/high is $0.95/$6.03.
Seeker Tec International, Inc. (SNTL)
PennyStocks24, HotStockCafe, Stock Analyzer, Wallstreetlivechat, and PennyStockSpy reported earlier on Seeker Tec International, Inc. (SNTL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
An aerial surveillance company, Seeker Tec International, Inc. has a principal subsidiary called Seeker Technologies Ltd. The Company is positioned to leverage major business opportunities in post-conflict and emerging markets worldwide. The group will have a range of Strategic Business Units (SBUs), each able to act as a lead in penetrating new markets. Seeker Tec International’s shares trade on the OTC Pink Current Information. The Company is based in Mandeville, Louisiana.
Seeker Tec International’s offering is supported by a unique multi-spectral imaging technology. This technology can detect surface and sub-surface objects utilizing ground penetrating radar. This is while mapping the area providing visual overlay of the graphic images. When further combined with other sensors such as infra-red and magnetometry, the technology additionally has applications in oil & gas exploration, agriculture, water exploration, as well as environmental survey.
Taking the main role in the aforementioned market penetration will be Mineseeker. They will deploy innovative, pioneering technology targeted at appreciably reducing the cost and increasing the productivity of landmine clearance. By way of the Mineseeker division, Seeker Tec has been primarily involved in the detection of landmines and unexploded ordnance (UXO), targeting a humanitarian market greater than $50 billion.
Mineseeker will identify minefields and release liberated land back for cultivation and other productive purposes. The Company will do this by the deployment of MIR™, the technology that Mineseeker pioneered. MIR™ has the ability to improve the productivity of current mine clearance methods by a factor of 500. It also substantially reduces the present cost by 90 percent.
In April of this year, Seeker Tec International announced that the Company recruited a senior executive to their management team. Mr. Issa Sawabini, a U.S. national, now living in the United Kingdom (UK), joined the group as Director for the Middle East and North Africa. As part of his role, Mr. Sawabini will develop strategic partnerships across the region with companies committed to the development of technology driven projects. Seeker Tec International will now offer a spectrum of services to industries looking for a higher quality aerial survey capability on a more efficient and cost effective basis.
Seeker Tec International, Inc. (SNTL), closed Monday's trading session at $0.052, up 1.96%, on 52,824 volume with 5 trades. The average volume for the last 60 days is 113,413 and the stock's 52-week low/high is $0.017/$0.219.
Global Earth Energy, Inc. (GLER)
PennyStocks24, Stock Analyzer, MarketWireStocks, InsideBulls, Penny Trackers, and Center Stage Stocks reported earlier on Global Earth Energy, Inc. (GLER), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Global Earth Energy, Inc. is an oil and gas exploration company based in Wilmington, North Carolina. They focus on developing prime prospects in the U.S. Global Earth Energy collaborates with some of the leading independent oil and gas drillers and operators in the industry. Consequently, they reduce the risks typically associated with the drilling of wells. The Company lists on the OTCQB.
In February of this year, Global Earth Energy announced a new extensive growth strategy centered on the acquisition of overriding royalty interests in oil and gas leases in the U.S. The Company will acquire leases from landowners with the objective of rolling up a multitude of leases covering several thousand acres. They believe this strategy will significantly enhance shareholder value. Through accruing a large land package, Global Earth Energy believes they will be poised as an attractive takeover target for larger oil and gas companies.
Recently, Global Earth Energy's President, Mr. Sydney A. Harland, announced that the Company would acquire an income-producing asset. This is the Naylor Apartment Complex, located at 2585 Naylor Road SE, Washington, DC 20020. This is a multi-unit (15) complex. Gross Revenues are $231,135.00; Expenses are $48,739.00; Net Operating Income is $182,396.00, and Net Income Available for Cash Flow is $151,997.00. Global Earth Energy is looking to broaden their corporate strategic direction.
In addition, in May, they announced that they will acquire a second income-producing asset, the Honeywell Apartment Complex, located at 2103-15 & 2115-17 Honeywell Avenue, Bronx, New York 10460. It is Multi-Units-198; the acquisition price was $26,000,000.00. Gross Revenue is $3,200,000.00 and Expenses are $1,500,000.00. Net Operating Income is $1,700,000.00, and Assumable Debt Service is $16,939,016.99 at 3.5 percent (Monthly Debt Payment: $76,063.75) (Annually: $912,765.00). The Net Income available for Cash Flow is $787,235.00.
Furthermore, in May, Global Earth Energy announced that the Company, via a Letter of Intent (LOI), intends to acquire a third income-producing asset, the Sunrise Highway Office Building, located at 381 Sunrise Highway, Lynbrook, New York 11563. This acquisition will only occur if Global Earth Energy and the seller of the property can execute a binding agreement of sale and purchase. Similarly, in May, the Company announced that they, through an LOI, intend to acquire an additional asset; Country Road Office Building, situated at 1670 Old Country Road, Plainview, New York 11803. Likewise, the acquisition will only occur if the Company and the seller of the property can execute a binding agreement of sale and purchase.
Global Earth Energy, Inc. (GLER), closed Monday's trading session at $0.0002, down 33.33%, on 33,326,333 volume with 10 trades. The average volume for the last 60 days is 22,787,687 and the stock's 52-week low/high is $0.0003/$0.14.
Ballard Power Systems, Inc. (BLDP)
SmarTrend Newsletters, The Street, PennyStocks24, Energy and Capital, Wall Street Resources, Pennybuster, StreetInsider, MonsterStocksPicks, Stock Stars, Alternative Energy, and Investor Ideas reported earlier on Ballard Power Systems, Inc. (BLDP), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Listed on the NASDAQ Global Market, Ballard Power Systems, Inc. is a worldwide leader in PEM (Proton Exchange Membrane) fuel cell technology. They principally engage in the design, development, manufacture, sale, and service of fuel cell stacks, modules, and complete systems for different applications in the motive and stationary power markets.
Established in 1979, Ballard Power Systems is based in Burnaby, British Columbia. The Company has a multi-market growth focus in fuel cell products. This focus propels greater revenue and margin potential. The expectation is that fuel cell applications will broaden in the mid-term. However, Ballard’s current focus remains deeply on commercial opportunities in backup power, distributed generation, material handling, as well as bus applications.
To date, the Company has designed and shipped almost 150 MW of hydrogen fuel cell technology. Ballard additionally focuses on the development of fuel processing components and systems; these are for use in fuel cell applications. The Company also provides engineering solutions for assorted fuel cell applications. Ballard, via their interests in Dantherm Power A/S, develops clean energy backup power systems through utilization of hydrogen fuel cell technology.
In June, Ballard Power Systems announced the launch of the next-generation ElectraGen™-ME backup power system for use in the telecom market. The fueling of this product is by methanol. ElectraGen™-ME features several enhancements that further improve reliability, durability, and ease of maintenance and servicing.
The Company’s ElectraGen™-ME systems are especially well suited for ‘extended runtime’ backup power needs. They offer proven financial and environmental advantages in comparison to batteries and diesel generators. These methanol-fuelled systems include a fuel reformer that converts HydroPlus™ (a methanol-water liquid fuel mixture) into hydrogen gas to power the fuel cell.
Another example of Ballard’s product offerings is their 6th Generation Module - FCvelocity-HD6 fuel cell module. Its basis is on the state of the art automotive fuel cell stack. The FCvelocity-HD6 fuel cell module offers a design ideal for integration into bus applications.
The next-generation Ballard fuel cell is at its core. This products establishes a new standard for cost, by way of design for volume manufacturing, and compatibility with customer system requirements.
Ballard Power Systems, Inc. (BLDP), closed Monday's trading session at $1.86, up 2.76%, on 576,459 volume with 978 trades. The average volume for the last 60 days is 1,279,248 and the stock's 52-week low/high is $0.5606/$2.39.
Health Enhancement Products, Inc. (HEPI)
Wall Street Resources reported earlier on Health Enhancement Products, Inc. (HEPI), OTCReporter, DrStockPick, PennyOmega, Stock Rich, CoolPennyStocks, HotOTC, HotStockChat did previously, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Health Enhancement Products, Inc. is part of the Drugs-Generic industry in the Healthcare sector. Listed on the OTC Markets’ OTCQB, the Company is a health & wellness company. They engage in the research and development of natural products derived from algae cultures for use as dietary supplements and food ingredients. These natural products undergo extraction from living algae grown in purified water. Health Enhancement Products has their corporate headquarters Bloomfield Hills, Michigan.
The Company’s dedication is to the study, development and commercialization of naturally derived compounds and bioactive molecules created by algal and bacterial hosts. These compounds and mixtures are extremely complex and dynamic in nature. They exhibit properties that, properly applied, can yield major results in subduing inflammation and allergic responses, up-regulating certain metabolic functions and down-regulating others. These are among other helpful effects.
The Company has begun study and development that target skeleton-muscular inflammation because of exertion and strenuous exercise; allergies and allergic reactions; cardiovascular disease risk; autoimmune disorders, as well as metabolic functions. Health Enhancement Products is working to develop proprietary and patented bioactive agents that may find their way into foods, supplements and possibly medicines. This involves the development of high-volume production techniques, stabilization and ingredient-oriented technologies so that the beneficial effects of these natural substances can be preserved once introduced into foodstuffs or liquids.
The Company markets their products through distributors. They offer ProAlgaZyme (PAZ), which is an infusion of algal metabolites diluted in purified water. The creation of these metabolites are by algae colonies living in special culture tanks housed at Health Enhancement Products’ facilities in Scottsdale, Arizona.
The algae colonies continuously produce the metabolites; these are filtered to drinking water purity. The metabolites undergo further separation and are re-diluted by a proprietary, patented process. Upon stabilization of the infusion, biologists check for bioactivity and the presence of metabolites using gel electrophoresis. The Company is re-evaluating the process of production; they will continue to use the infusion for research and clinical studies only.
Health Enhancement Products, Inc. (HEPI), closed Monday's trading session at $0.36, up 3.60%, on 63,748 volume with 24 trades. The average volume for the last 60 days is 123,114 and the stock's 52-week low/high is $0.09/$0.53.
Balmoral Resources Ltd. (BALMF)
Vantage Wire reported recently on Balmoral Resources Ltd. (BALMF), The Online Investor, and BabyBulls did previously, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Balmoral Resources Ltd. is a gold exploration and development company with corporate headquarters in Vancouver, British Columbia. They concentrate on the acquisition, aggressive exploration, and development of gold projects/resources in the foremost gold districts of North America. Their portfolio of advanced and early stage gold exploration projects is in the Abitibi greenstone belt. Balmoral Resources’ shares trade on the OTCQX International, and on the TSX Venture Exchange under the trading symbol “BAR.V”.
The Abitibi greenstone belt of ancient rocks stretches through Quebec and eastern Ontario. It is home to the Detour Lake, Casa Berardi, Timmins, Kirkland and the Val-D'Or gold mining camps. Balmoral resources is focusing on high-grade gold discoveries along this Detour Gold Trend in the Province of Quebec.
The Company has initial plans in place for the summer 2013 exploration program on their Detour Trend Gold Project. Balmoral’s Board of Directors approved an exploration budget of $3.8 million dollars for the balance of the 2013 calendar year. The Company had a highly successful expansion program that completed during the winter of 2013 on the Company's Martiniere Property.
Balmoral announced at the end of May that the remaining drill results from the winter 2013 drill program further expands the Bug Lake Gold Zone, further delineates the Martiniere West Zone, provides indications of continuity for an earlier intersected high-grade gold-silver discovery in the Martiniere East area, and suggests the presence of another Bug Lake parallel (north-south trending) gold bearing structure on the Property.
Their summer 2013 program will center on the further delineation and expansion of their high-grade gold discoveries at Martiniere and on continued advancement of several high-priority targets throughout the 650 square kilometer Detour Gold Trend Project area. This includes discoveries in the Grasset and Detour East areas. The anticipation is that drilling will begin in mid-July and continue through the summer months. The objective is to complete between 12,000 and 15,000 meters of drilling between July and early October.
Furthermore, GTA Resources and Mining, Inc. notified Balmoral Resources that their Phase 4 drilling program on Balmoral’s Northshore Property in Ontario has completed. Results from three additional holes are currently pending. This includes an initial test of the former producing Northshore Mine system.
Balmoral Resources Ltd. (BALMF), closed Monday's trading session at $0.305, up 7.58%, on 211,550 volume with 32 trades. The average volume for the last 60 days is 29,116 and the stock's 52-week low/high is $0.26/$1.269.
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.251, off by 7.04%, on 61,481 volume with 22 trades. The stock’s average daily volume over the past 60 days is 282,889, and its 52-week low/high is $0.10/$2.67.
Rainbow Coral Corp. took some time out today to praise the fundraising efforts of JV partner, Berlin-based, TheraKine, Ltd., emboldened by growing receptivity to their cutting-edge drug delivery technologies. Technologies which today knock ever louder on the door of a market set to swell to $81.5B in just the top 10 delivery techs alone and which dovetail exceptionally well with the medical and research innovations of RBCC's biotech division, Rainbow BioSciences.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC Praises Partner TheraKine’s Fundraising Results in $60 Billion Drug Delivery Market
RBCC Explores New Funding for Expansion
RBCC Poised To Gain Share Of $142 Billion Market
StreamTrack, Inc. (STTK)
The QualityStocks Daily Newsletter would like to spotlight StreamTrack, Inc. (STTK). Today, The Aristocrat Group Corp. closed trading at $0.10, up 42.86%, on 5,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 10,949, and its 52-week low/high is $0.0638/$4.80.
StreamTrack, Inc. (STTK), a digital media and technology services company, provides audio and video streaming and advertising services through its RadioLoyalty™ Platform to a global group of internet and terrestrial radio stations, internet radio guides, and other broadcast content providers. The company's platform powers a web-based and mobile player that manages streaming audio and video content, social media engagement, and ad serving.
StreamTrack offers its platform directly to broadcasters and integrates or white labels its technologies with web-based internet radio guides and other web-based content providers. With StreamTrack technology, broadcasters and publishers are able to maximize their revenue while decreasing expenses, while advertisers are provided with a cost-effective means to reach their target audience from one source at scale.
WatchThis™, StreamTrack's patent-pending technology designed to provide web, mobile, and IP television streaming services that are e-commerce enabled within streamed content, could revolutionize the entertainment industry by combining original network content with interactive product placement. Recognizing the convergence of traditional televised advertisement and internet technology, StreamTrack is advancing its WatchThis™ technology to lead the revolution taking place.
StreamTrack is dedicated to continually creating and managing innovative technology products to provide broadcasters and content owners the most advanced solutions available in the marketplace. Fully committed to also increasing and protecting shareholder value, the management team carefully executes operational, development, and marketing programs with the primary aim of maximizing the company's growth potential and profitability. Disclaimer
StreamTrack, Inc. Company Blog
StreamTrack, Inc. News:
StreamTrack's RadioLoyalty Platform™ Adds Over 3,000 Stations
StreamTrack and One World Media Group Announce Agreement With Monaco Media International
StreamTrack Announces Alliance to Potentially Reach Over 300 Million Registered PPTV Users
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.29, up 13.73%, on 23,750 volume with 7 trades. The stock’s average daily volume over the past 60 days is 57,641, and its 52-week low/high is $0.041/$0.98.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Pharmaceuticals, Inc. Enters $50M Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
Rafarma Pharmaceuticals, Inc. Announces Engagement of QualityStocks Investor Relations Services
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.235, up 1.73%, on 91,848 volume with 31 trades. The stock’s average daily volume over the past 60 days is 93,050, and its 52-week low/high is $0.161/$0.41.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting
International Stem Cell Subsidiary Lifeline Skin Care Expands Asian Distribution
International Stem Cell Corporation Initiates IND-Enabling Study in Parkinson's Disease Program
Today before the opening bell, Rainbow Coral applauded the fundraising results achieved by joint venture partner TheraKine, Ltd.
“TheraKine has done a tremendous job of bringing in outside funds to help push its innovations further into a hungry marketplace,” said RBCC CEO Patrick Brown. “The interest in TheraKine’s new drug delivery solutions is a fantastic illustration of this new system’s incredible market potential.”
Rainbow Coral signed a joint venture agreement with TheraKine earlier this year to help market and develop a revolutionary, sustained-release drug delivery platform designed to make local delivery of biologic agents and small molecules safer, more effective, and more convenient. TheraKine’s novel, patented technologies have the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.
As TheraKine concentrates on outside fundraising in order to market these technologies around the globe, RBCC is seeking out interested healthcare providers with clients that would highly value TheraKine’s advanced sustained-release delivery system.
The global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies alone could grow to $81.5 billion by 2015.
RBCC is dedicated to delivering new medical research and technologies. For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com/investors.html.
Rafarma Pharmaceuticals has made a significant investment in a 270,000-square-foot state-of-the-art production facility in the economic development zone in Terbuny, Lipetsk Region, south of Moscow. This sprawling, multi-profile pharmaceutical plant has the capability and space to produce all types and forms of medical drugs of various pharmacological groups.
The facility was designed to accommodate a fair share of the burgeoning Russian pharmaceutical market, which is growing in tremendous leaps and bounds following an aggressive development campaign launched by the Russian government in 2010.
Upon full production, which is expected to commence later this year, Rafarma anticipates being one of the leaders in the nation’s “big pharma.”
The QualityStocks Production team recently compiled an informative video on Rafarma, specifically highlighting the company’s facility and support the company has received from the Ministry of Industry and Trade of the Russian Federation, The Russian Ministry of Health, and The Administration of Lipetsk.
“It’s one of the most ambitious projects in Russian industry in recent years … this facility permits us to introduce into our manufacturing practice modern scientific developments, and it permits us to improve the technology of our production constantly,” Julia Andryshokova , member of ZAO Rafarma’s board of directors, says in the video. “Our strategy does permit us to see ourselves at the top of leaders of Russia’s pharmaceutical market.”
To view the entire production, visit www.qualitystocks.net/videos.php
For more information on Rafarma, visit www.rafarma.com
Ask any physician or health care professional what America’s biggest single health problem is and you will likely get an answer that points to cardiovascular disease and the lifestyle issues that promote it, such as obesity. Heart disease has long been the number one killer in the U.S., and various lifestyle factors have increasingly been implicated as a principal cause. Specifically, poor eating habits and a sedentary lifestyle have been shown to encourage obesity and type 2 diabetes. Type 2 diabetes, in turn, can lead to a number of serious problems, one of which is cardiovascular disease.
The link between lifestyle, diabetes, and cardiovascular disease is a major focus because of the numbers involved. The U.S. now has the highest rate of obesity in the world, with roughly 30% of all Americans listed as obese. The growth in obesity has helped fuel an alarming growth rate in diabetes, with some states experiencing a doubling of the diabetes rate in just 5 years. Diabetes is now known to feed heart disease, and approximately 600,000 people die annually in the U.S. from heart disease. Such numbers have generated a vast and growing market for health products and drugs that can address this chain of disease which threatens to cripple entire generations and dramatically affect the nation’s economy.
California-based Cardium Therapeutics, a health sciences and regenerative medicine company, is unique in that its products directly address all three of these major markets.
• Cardium’s lifestyle subsidiary, To Go Brands, produces all-natural health supplements that are designed for easy and convenient use, helping people to get the nutrition they need while losing weight.
• Cardium’s Excellagen is an FDA-approved easy-to-use gel that has been shown to speed and improve the healing process for wounds, including their primary target market of foot wounds caused by diabetes.
• Cardium’s Generx is the first-of-its-kind drug that actually promotes the growth of blood vessels around the heart, enhancing blood flow for heart disease patients, unlike other heart drugs that simply address the pain.
For additional information, visit www.CardiumTHX.com
Raptor Resources Holdings today posted the 2nd edition of RaptorNews, an online publication that provides the latest company news. This issue announces that the company is forging an alliance with Steinbock Minerals Ltd. and Yasheya Ltd. via a Memorandum of Understanding. The partnerships being pursued represent the missing link to Raptor Resources’ ability to establish a strong presence in the barite marketplace as an emerging high-quality source.
Partnering with these two companies will surround Raptor Resources with established industry leaders in the worldwide distribution, marketing, sales, and delivery of industrial minerals. During the due diligence period, the companies will be working together at the Port of Beira, Mozambique, along with Mozambique and Zimbabwe Rail Authorities for seamless integration.
Future company announcements will be made first via the Web site before a press release is distributed. Investors will always get the latest news and information at www.raptorresourcesholdings.com/corporate-briefing-2.
For more information on Raptor Resources, visit www.raptorresourcesholdings.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Requests Orphan Drug Designation for Treatment of HPV-Associated Anal Cancer with ADXS-HPV
- Cardium Therapeutics, Inc. (CXM) Announces Temporary Adjournment of Annual Meeting To Be Reconvened On July 2, 2013
- DoMark International, Inc. (DOMK) Engages Leading Global Designer to Develop a New Luxury Range of Accessory Products for the Apple iPad for the $200 Billion Luxury Product Market
- Frozen Food Gift Group Inc. (FROZ) Announces Partnership To Launch Groundbreaking Ice Machine Sanitation Technology
- GlobalWise Investments, Inc. (GWIV) Adds Toshiba Business Solutions AZ/CO as New Channel Sales Partner
- GNCC Capital, Inc. (GNCP) Completes the Acquisition of the White Hills Gold Properties
- GRILLiT®, Inc. (GRLT) Postpones Record Date for Common Stock Dividend
- International Stem Cell Corp. (ISCO) to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting
- Low Carbon Technologies International, Inc. (LWCTF) Plans to Announce 6 Month YTD Financials
- Mabwe Minerals Inc. (MBMI) Announces Engagement of QualityStocks Investor Relations Services
- Rafarma Pharmaceuticals, Inc. (RAFA) Enters $50M Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
- Rainbow Coral Corp. (RBCC) Praises Partner TheraKine’s Fundraising Results in $60 Billion Drug Delivery Market
- Raptor Resources Holdings Inc. (RRHI) Announces Engagement of QualityStocks Investor Relations Services
- Solar Wind Energy Tower, Inc. (SWET) CEO Featured in Exclusive QualityStocks Interview
- StreamTrack, Inc. (STTK) RadioLoyalty Announces the Release of Its New UniversalPlayer™
- The Aristocrat Group Corp. (ASCC) Targets Booming Texas Market for Exclusive Beverage Distribution
- The Guitammer Company Inc. (GTMM) ButtKicker Gamer2, Two "Butts" Are Better Than One
- VentriPoint Diagnostics Ltd. (VPTDF) Announces Closing of Private Placement and Corporate Update
- VistaGen Therapeutics, Inc. (VSTA) Provides Update on $36 Million Strategic Financing Agreement